Pathogenesis and treatment of ANCA-associated systemic vasculitis
A D Salama MA MRCP SECTION OF NEPHROLOGY, 17 NOVEMBER 1998 The primary systemic vasculitides are characterized by necrotizing inflammation of blood vessels and encompass several different disease entities. Their classification, clarified at the Chapel Hill Consensus Conferencel, relies chiefly on the size of vessel involved (see Figure 1 ) as well as certain clinical features. Those conditions affecting the kidney damage small blood vessels within it and cause a focal necrotizing glomerulonephritis (Figure 2 ), often reaching end-stage renal failure within weeks or months. Microscopic polyangiitis, Wegener's granulomatosis, Churg-Strauss syndrome and renal limited vasculitis all affect small vessels, and are generally associated with antineutrophil cytoplasmic antibodies (ANCA). This group of diseases, termed ANCA-associated systemic vasculitis, is responsible for approximately 5-6% of cases presenting with acute renal failure and has an incidence of up to 30 cases/million/year. This appears to be increasing, partly as a result of better diagnosis and widening use of ANCA testing. Other vasculitic syndromes affecting the kidney may be secondary to 'immune complex' systemic diseases such as systemic lupus erythematosus, Henoch-Schonlein purpura or essential mixed cryoglobulinaemia, drugs such as propylthiouracil and hydralazine, and infections such as infective endocarditis.
In this paper, inspired partly by contributions to a meeting of the RSM Section of Nephrology, I highlight recent developments in the science of systemic vasculitis. More general reviews can be found elsewhere24. There is considerable evidence that ANCA has a role in initiating disease. There is some correlation between the specificity of ANCA and disease features; most patients with active Wegener's granulomatosis have C-ANCA directed against PR3, whereas in renal limited vasculitis, Churg-Strauss syndrome and microscopic polyangiitis greater numbers of patients have P-ANCA14.
There are other antigens with which ANCA react, but no clear disease correlations have been found. ANCA levels correlate with disease activity. In our own series of patients persistent levels are predictive of relapse, and rising levels of ANCA can precede relapse by one to three months15-17. One study in patients with evidence of rising ANCA titres showed that relapse rates could be reduced by increasing immunosuppression preemptively'8. Our own practice is to maintain treatment levels in the face of persistent or rising titres and monitor closely for signs of relapse'4. 
